During a tough 2016, only three large drugmakers added jobs and five cut them. AbbVie's roster grew the most, followed by Roche and Lilly.
Industry watchers speculated before the release of AstraZeneca’s lung cancer combo data that a flopped trial could prime the British drugmaker for a takeover.
Two weeks after winning approval and one month ahead of its previous launch timeline, Puma Biotechnology introduced new cancer medication Nerlynx.
Facing mounting pressure to make an acquisition, Gilead executives were likely relieved to report an unexpected surge of second-quarter growth.
Novartis is hunting for bolt-on deals, but too-high biotech valuations have forced its M&A scouts to eye early-stage assets.
Now that Valeant has finally found a buyer for Obagi, the sale isn't raising nearly as much cash as the company might have wanted.
If you were excited about Tesaro selling, you might want to keep an eye on Incyte next.
Even without U.S. tax reforms expected to spur M&A action, biopharma dealmaking hasn’t slowed down, and nor should industry watchers assume it will.
Though not nearly on the scale of Sanofi's runs at Medivation or Actelion, the Protein Sciences buyout promises a boost for its flu vaccines lineup.
Two weeks after their bid failed to garner key support from shareholders, Stada’s wannabe buyers are back.